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Abstract
Background: Germline mutations in a tumor suppressor gene FLCN lead to development of fibrofolliculomas, lung cysts and
renal cell carcinoma (RCC) in Birt-Hogg-Dube ´ syndrome. TFE3 is a member of the MiTF/TFE transcription factor family and
Xp11.2 translocations found in sporadic RCC involving TFE3 result in gene fusions and overexpression of chimeric fusion
proteins that retain the C-terminal DNA binding domain of TFE3. We found that GPNMB expression, which is regulated by
MiTF, was greatly elevated in renal cancer cells harboring either TFE3 translocations or FLCN inactivation. Since TFE3 is
implicated in RCC, we hypothesized that elevated GPNMB expression was due to increased TFE3 activity resulting from the
inactivation of FLCN.
Methodology/Principal Findings: TFE3 knockdown reduced GPNMB expression in renal cancer cells harboring either TFE3
translocations or FLCN inactivation. Moreover, FLCN knockdown induced GPNMB expression in FLCN-restored renal cancer
cells. Conversely, wildtype FLCN suppressed GPNMB expression in FLCN-null cells. FLCN inactivation was correlated with
increased TFE3 transcriptional activity accompanied by its nuclear localization as revealed by elevated GPNMB mRNA and
protein expression, and predominantly nuclear immunostaining of TFE3 in renal cancer cells, mouse embryo fibroblast cells,
mouse kidneys and mouse and human renal tumors. Nuclear localization of TFE3 was associated with TFE3 post-
translational modifications including decreased phosphorylation.
Conclusions/Significance: Increased TFE3 activity is a downstream event induced by FLCN inactivation and is likely to be
important for renal tumor development. This study provides an important novel mechanism for induction of TFE3 activity in
addition to TFE3 overexpression resulting from Xp11.2 translocations, suggesting that TFE3 may be more broadly involved
in tumorigenesis.
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Introduction
Genetic studies have revealed several tumor suppressor genes
[von hippel lindau (VHL), fumarate hydratase (FH), succinate dehydrogenase
subunit B (SDHB) and folliculin (FLCN)] and proto-oncogenes
(hepatocyte growth factor receptor MET) that are responsible for the
development of renal cell carcinoma (RCC) [1]. In addition, two
groups of transcription factors have been implicated in the
development of RCC. Hypoxia-inducible factors (HIFs) were
originally reported to be stabilized by the inactivation of the VHL
tumor suppressor gene [2]. HIF stabilization is also correlated with
mutations in FH or SDHB and is important in tumor cell growth
and angiogenesis [3,4]. TFE3 and TFEB, members of the
MiTF/TFE transcription factor family, are highly expressed in
the nucleus as a result of chromosomal translocations and are
responsible for the development of juvenile renal cancer [5,6].
However, the dysregulation of TFE3 or TFEB as a consequence of
mutations in other tumor suppressor genes has not been reported.
Here we investigated the regulation of TFE3 activity by the FLCN
tumor suppressor gene.
Translocation renal cell carcinomas (RCCs) are rare tumors
mainly reported in children and young adults [7]. They are
classified as a distinct subtype and are characterized by various
translocations that frequently involve TFE3 and, infrequently,
TFEB. Both TFE3 and TFEB harbor basic helix-loop-helix-
leucine zipper (bHLH-LZ) DNA binding domains and belong to
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microphthalmia transcription factor (MiTF) and transcription
factor EC (TFEC) [8]. At least 5 genes have been reported to fuse
with TFE3 and are predicted to produce ASPL-TFE3, PRCC-
TFE3, NonO-TFE3, CLTC-TFE3 and PSF-TFE3 fusion proteins
[7]. Importantly, the translocations are associated with overex-
pression of the fusion proteins, which can be identified by
distinctive nuclear TFE3 staining. In addition, the resulting fusion
proteins retain the bHLH-LZ DNA binding domain of TFE3,
which may be important for tumorigenesis.
MiTF/TFE transcription factors bind to consensus M-box
sequences (TCATGTG, CATGTGA or TCATGTGA) or the E-
box sequence (CACGTG) either as homodimers or heterodimers
[8,9]. MiTF is a master regulator of melanocyte development and
a key transcription factor in melanoma progression. It regulates
genes involved in melanocyte survival and function, and
melanoma cell proliferation. MiTF is often amplified in advanced
melanomas and functions as an oncogene [10]. MiTF/TFE
transcription factors show functionally redundant oncogenic
activity. MiTF knockdown decreased viability of clear cell sarcoma
cells but TFE3 or TFEB expression rescued their viability [11].
Reciprocally, TFE3 knockdown decreased viability of papillary
renal carcinoma cells that harbor TFE3 translocations but were
rescued by expression of MITF.
GPNMB was first cloned from a melanoma cell line and is
expressed at high level in many melanoma cell lines. Its expression
is directly regulated by MiTF through highly conserved M-box
sequences in the promoter [12,13]. GPNMB is a glycosylated
transmembrane protein and plays a role in osteoblast and
osteoclast differentiation, and cancer cell metastasis [14]. It has
been suggested as a therapeutic target in melanoma, glioblastoma
and breast cancer [15–17]. An antibody-drug conjugate, CR011-
vcMMAE, targeting GPNMB effectively induced complete
regression of xenograft tumors expressing GPNMB [15].
CR011-vcMMAE is currently under phase I and II trials as a
treatment for melanoma and breast cancer [18].
Birt-Hogg-Dube’ (BHD) syndrome is characterized by the
development of fibrofolliculomas, lung cysts and renal carcinoma
and caused by germline mutations in the folliculin (FLCN) gene [19–
21]. FLCN forms a complex with novel folliculin-interacting
proteins 1 and 2 (FNIP1 and FNIP2), and 59-AMP-activated
protein kinase (AMPK), a kinase that negatively regulates
mammalian target of rapamycin (mTOR) [22,23]. The functional
role of FLCN has been suggested through monitoring mTOR
signaling after FLCN inactivation in cells and tissues. However,
conflicting mTOR signaling or S6 phosphorylation results were
reported [24–28]. Therefore regulation of mTOR activities by
FLCN could be context dependent. Thus far there are no evident
downstream target molecules that are strictly regulated by FLCN.
Renal carcinoma development is correlated with FLCN
inactivation caused by naturally occurring germline mutations in
human BHD patients, the Nihon rat model (C insertion in exon 3
of rat Flcn), German Shepherd dogs resulting in renal cystadeno-
carcinoma and nodular dermatofibrosis (RCND; H255R mutation
in canine Flcn) and by genetically manipulated deletions in mice
[21,24–30]. Flcn heterozygous knockout mice developed renal
neoplasia and cysts as they aged, with concomitant loss of the
wildtype copy of Flcn [26]. On the other hand, kidney specific
(cadherin 16)-Cre (Ksp-Cre)-mediated Flcn inactivation induces
renal cell hyperproliferation and a polycystic kidney phenotype in
mice [24].
In this study, we identified GPNMB as a downstream target that
was induced by FLCN inactivation. GPNMB expression was
investigated in renal cancer cells, mouse embryo fibroblast cells,
and mouse and human renal carcinomas under conditions of
FLCN inactivation. In addition, we examined the relationship
between the FLCN tumor suppressor gene and the proto-oncogene
TFE3, using GPNMB expression as a surrogate marker.
Results
GPNMB expression was elevated by FLCN inactivation or
MiTF/TFE3 expression
Previously in an effort to understand FLCN function, we
searched for differentially expressed genes in cells expressing
mutant FLCN compared to wildtype FLCN by gene expression
microarray analysis. We identified ,400 genes that were up or
down-regulated more than 2-fold by the expression of wildtype
FLCN [31]. Through a verification process including confirmation
by RT-PCR and expression induction or reduction upon transient
expression of FLCN, the number of genes for further analysis was
reduced to 15 (Table S1). Twelve of 15 genes were upregulated
and 3 of 15 genes were down regulated by adenoviral vector-
mediated FLCN expression in UOK257 FLCN-null cells. We
looked for a transcription factor that mediated this regulation.
While evaluating the promoters of each gene by bioinformatics, we
found that one of the 15 genes, GPNMB, is regulated by a
transcription factor known as microphthalmia transcription factor
(MiTF) [12,13]. The GPNMB promoter harbors a highly
conserved M box sequence, which is recognized by MiTF/TFE
transcription factors (Fig. 1A). We examined whether MiTF and
TFE3 transcription factor expressions were correlated with
GPNMB expression (Fig. 1B). As in a previous report [32], we
found high GPNMB expression in an MiTF-positive melanoma
cell line, SK-MEL-28 (Fig. 1B). GPNMB expression was also high
in the UOK146 cell line (Fig. 1B) that was established from a
sporadic kidney tumor harboring a chromosomal translocation,
t(X;1)(p11.2;q21), which expressed a high level of the resulting
gene fusion product, PRCC-TFE3 [5]. Interestingly, although
UOK257 cells expressed a high level of GPNMB similar to SK-
MEL-28 and UOK146 cells, only a low level of MiTF was
detected. On the other hand, a moderate level of two TFE3
isoforms, with molecular weights of 72 kDa and 89 kDa, were
detected in UOK257 and its sublines, and in 293FT cells. The
parental UOK257 cell line and a mutant FLCN (H255R)
UOK257 cell line showed higher levels of GPNMB expression
than the wildtype FLCN-restored cell lines (UOK257-2 and
UOK257-4) (Fig. 1B). In accordance with GPNMB protein
expression, GPNMB mRNA expression showed a similar pattern
(Fig. S1A). However, MiTF and TFE3 levels were not affected by
FLCN expression. HT1080 and 293FT cells expressed MiTF or
TFE3 proteins at comparable levels to SK-MEL-28 and UOK257,
respectively, but neither 293FT cells nor HT1080 cells expressed
GPNMB (Fig. 1B). This suggested that MiTF and TFE3 may not
be constitutively active but may need stimulation or additional
factors to induce GPNMB expression.
GPNMB expression was regulated negatively by FLCN
and positively by TFE3
In order to examine whether TFE3 regulates GPNMB
expression, TFE3 expression was knocked down by siRNA in
UOK257 and UOK146 cells. TFE3 siRNAs reduced both 72 kDa
and 89 kDa protein bands in UOK257 cells, which were
recognized by TFE3 antibody, confirming that both proteins were
TFE3. UOK146 expressed only one PRCC-TFE3 fusion protein
migrating similarly to the larger TFE3 protein and its expression
was reduced by TFE3 siRNA. Interestingly, TFE3 knockdown
reduced GPNMB expression in both UOK257 and UOK146 cell
TFE3 Activity Induced by FLCN Inactivation
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expression only in FLCN-expressing cells (UOK257-2), but not in
FLCN-null cells (UOK257; Fig. 1C). GPNMB expression was
higher in UOK257-2 and UOK146 cells with FLCN and TFE3
double knockdown compared to those cells with TFE3 knockdown
alone (Fig. 1C and 1D).
To examine whether GPNMB expression induced by FLCN
inactivation was through transcriptional regulation, we measured
GPNMB mRNA expression after FLCN knockdown by siRNAs or
shRNA in the UOK257-2, HT1080 and MEF cell lines. When
FLCN expression was reduced, GPNMB mRNA levels were
increased 1.5,3 fold compared to the controls (Fig. 1E).
Conversely, adenovirus mediated wild-type FLCN or FLCN/
FNIP1 expression suppressed GPNMB mRNA expression more
than 2 fold, but mutant FLCN (c.1285dupC, most frequent
mutation in BHD syndrome), mutant FLCN/FNIP1 or FNIP1
alone did not suppress GPNMB expression in UOK257 cells
(Fig. 1F). In accordance with the GPNMB mRNA expression, the
GPNMB protein level was also induced by FLCN knockdown and
reduced by adenovirus mediated-wildtype FLCN expression but
not by mutant FLCN expression (c.1285dupC) (Fig. S1B and
S1C).
Figure 1. GPNMB expression was regulated positively by TFE3 and negatively by FLCN. (A) A highly conserved M box sequence
(TCACATG) was identified in the GPNMB promoter that is recognized by the MITF/TFE3 transcription factor family. GPNMB promoter sequences from 8
representative mammalian species were obtained from the Ensembl database (www.ensembl.org) and were aligned for comparison using ClustalX
(1.8) software (www.clustal.org). (B) GPNMB expression was examined in various cell lines by Western blot analysis. Two different TFE3 proteins (72
and 89 kDa) are indicated by arrows. (C–D) Regulation of GPNMB expression by TFE3 and FLCN knockdown. UOK257, UOK257-2 and UOK146 cells
were transfected with control siRNA (sc1) or siRNAs targeting FLCN, TFE3 or FLCN/TFE3 and were harvested in 3 days for the analysis of protein
expression. The ratios of TFE3
89 kDa to TFE3
72 kDa proteins are indicated. (E) FLCN knockdown induced GPNMB mRNA expression in UOK257-2, HT1080
and MEF cells. (F) Adenovirus-mediated FLCN or FLCN/FNIP1 overexpression suppressed GPNMB mRNA expression in UOK257 cells. GPNMB and FLCN
expressions were analyzed by quantitative RT-PCR.
doi:10.1371/journal.pone.0015793.g001
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GPNMB promoter activity was analyzed in HT1080 cells that
express endogenous FLCN. Basal GPNMB promoter activity was
not reduced by ectopic expression of FLCN but was reduced by
expression of FNIP1 (30%; student’s t-test, P=0.06) or FNIP2
(50%; P,0.01) and synergistically by FLCN/FNIP1 (60%;
P,0.01) or FLCN/FNIP2 (70%; P,0.01) (Fig. 2A). Similarly,
TFE3-induced GPNMB promoter activity was not suppressed by
FLCN but was suppressed by FNIP1 (20%; P,0.05) or FNIP2
(20%; P,0.01) and further by FLCN/FNIP2 (40%; P,0.01)
suggesting that both FLCN and FNIP are needed in the
suppression of TFE3 activity (Fig. 2A). However, MiTF-induced
GPNMB promoter activity was not reduced by FLCN or FLCN/
FNIPs. Electrophoretic mobility shift assays (EMSA) confirmed
that TFE3 bound to the GPNMB promoter sequence containing
the wildtype M box but not a mutant M box (Fig. 2B). TFE3
binding to the GPNMB promoter sequence was validated by the
disappearance of the probe/TFE3 band with TFE3 antibody
possibly through a supershift of the band. Although we could not
observe a discrete supershifted band, the increased intensity of the
upper non-specific band by the addition of TFE3 antibody
suggested a supershift of the TFE3/probe band.
TFE3 post-translational modifications were affected by
FLCN expression
Two different molecular weight TFE3 proteins (72 kDa and
89 kDa) were frequently observed in many cell types, including
UOK257, 293FT, mouse embryonic fibroblasts (MEFs) and Flcn
knockout mouse kidneys (Fig. 1B, 3A and 3B). In addition, both
TFE3 proteins were produced in UOK257 from a single
adenovirus-delivered full-length mouse TFE3 cDNA suggesting
protein modification. Although the molecular weight of TFE3 is
62 kDa, it was reported that TFE3 protein from B16 melanoma
cells and mouse splenocytes migrates close to 72 kDa [33]. Thus
the lower 72 kDa protein can be regarded as the native form of
TFE3 and designated as TFE3
72 kDa. The upper 89 kDa TFE3
protein, designated as TFE3
89 kDa is likely to be a product of post-
translational modification of TFE3. In both MEFs and mouse
kidneys, FLCN inactivation was correlated with an increased level
Figure 2. Regulation of TFE3-driven GPNMB promoter activity by FLCN and FNIP1/2. (A) FLCN/FNIP1/2 suppressed basal and TFE3-induced
but not Mitf-induced GPNMB promoter activity. HT1080 cells were transfected with GPNMB promoter-luciferase-reporter construct along with FLCN,
FLCN/FNIP1 or FLCN/FNIP2. Promoter activity was calculated after normalizing firefly luciferase reporter activity to TK-promoter driven renilla
luciferase activity. (B) EMSA showed TFE3 bound to GPNMB promoter sequence containing wildtype M box (wt probe) but not mutant M box (mt
probe). *, non-specific bands.
doi:10.1371/journal.pone.0015793.g002
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89 kDa compared to TFE3
72 kDa, and increased GPNMB
protein and mRNA expression (Fig. 3A, 3B, S1D and S1E). In
addition, the ratio of TFE3
89 kDa to TFE3
72 kDa was lower in
UOK257-2 (ratio=0.4) compared to UOK257 (ratio=1.7) but it
was increased in response to FLCN knockdown by siRNA
(ratio=0.9) (Fig. 1C). Not only the ratio of TFE3
89 kDa to
TFE3
72 kDa, but also the migration pattern of TFE3
72 kDa was
different between UOK257 and UOK257-2. The smeared
additional band just above TFE3
72 kDa disappeared after FLCN
knockdown (Fig. 1C, arrow head). To better examine the effect of
FLCN expression on TFE3 post-translational modifications,
FLCN and TFE3 were ectopically expressed in UOK257 cells
using adenoviral vectors, and the cell lysates were separated by
either 4–20% or 7.5% SDS PAGE (Fig. 3C). We could see doublet
bands for TFE3
72 kDa and TFE3
89 kDa proteins in UOK257 cell
lysates when separated by 7.5% SDS PAGE (Fig. 3C, lane 2).
However, we could observe at least two or more slower migrating
bands for each protein in UOK257-2 cells (Fig. 3C, lane 8, red
vertical bars). In addition, ectopic expression of wildtype FLCN
and FLCN/FNIP1 induced post-translational modifications in
both TFE3 proteins in UOK257 cells (Fig. 3C, lanes 3 and 5). We
then examined whether the multiple slower migrating TFE3 bands
were due to phosphorylation. TFE3 proteins were immunopre-
cipitated from UOK257 and UOK257-2 cell lysates and were
treated with protein phosphatase. As shown in Fig. 3E, the slower
migrating smeared bands were down-shifted and became a single
sharp band for each TFE3 protein, indicating that those slower
migrating bands were phosphorylated TFE3 proteins. TFE3
phosphorylation was also examined in MEFs by separating cell
lysates through 7.5% SDS PAGE. As shown in Fig. 3D, both
Figure 3. FLCN inactivation was correlated with post-translational modifications and nuclear accumulation of TFE3. (A–B) Increased
Gpnmb expression and increased ratio of TFE3
89 kDa to TFE3
72 kDa was correlated with Flcn inactivation in MEFs and mouse kidneys. (C) Adenovirus-
mediated FLCN expression increased phosphorylation of both TFE3
89 kDa and TFE3
72 kDa proteins in UOK257 cells. (D) Higher level of TFE3
phosphorylation was observed in Flcn
f/2 MEFs compared to Flcn
2/2 MEFs. (E) TFE3 phosphorylation was examined by treating TFE3
immunoprecipitates with or without protein phosphatase (PPase). Lys, cell lysate. (F) TFE3 subcellular localization was analyzed by fractionating
cells into cytoplasmic (Cyto), soluble nuclear (Nuc/sol) and insoluble nuclear (Nuc/insol) fractions. The ratio of TFE3
89 kDa to TFE3
72 kDa was calculated
from the band intensities of TFE3 by densitometry (S.E.). S.E., short exposure; L.E., long exposure.
doi:10.1371/journal.pone.0015793.g003
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72 kDa and TFE3
89 kDa proteins were more phosphorylated
in Flcn heterozygote MEFs compared to Flcn-inactivated MEFs
similar to UOK257-2 and UOK257 (red vertical bars).
FLCN induced cytoplasmic accumulation of TFE3
Transcription factor activity can be regulated by modulating
subcellular localization, which is often achieved through post-
translational modification including phosphorylation and dephos-
phorylation. Translocation of MiTF and TFEB into the nucleus in
response to stimulus has been studied but nucleocytoplasmic
shuttling of TFE3 has not been reported [34,35]. Since TFE3 post-
translational modifications were affected by FLCN, we examined
whether FLCN expression could regulate TFE3 subcellular
localization after cellular fractionation to yield cytoplasmic, soluble
and insoluble nuclear fractions. Interestingly, endogenous TFE3
nuclear accumulation was negatively regulated by FLCN expres-
sion (Fig. 3F). TFE3 was mainly localized in the insoluble nuclear
fraction of UOK257 cells. However, adenovirus-mediated FLCN
expression increased TFE3 levels in the cytoplasmic fraction and
decreased TFE3 levels in the insoluble nuclear fraction. The ratio
of TFE3
89 kDa to TFE3
72 kDa was higher in the nuclear fraction
(1.2) than in the cytoplasmic fraction (0.3) in UOK257 cells;
however, the ratio was reduced in both fractions by wildtype but
not mutant FLCN (c.1285dupC) expression (Fig. 3F). Nonetheless
the degree of reduction was greater in the cytoplasmic fraction
(0.3=.0.1, 67%) than in the nuclear fraction (1.2=.0.7, 42%).
In accordance with the fractionation result, immunocytochem-
ical staining of adenovirus-delivered TFE3 proteins showed
nuclear localization of TFE3 in UOK257 cells (Fig. 4A). Transient
FLCN expression induced cytoplasmic accumulation of TFE3
proteins in UOK257 cells. In addition, we observed that not only
adenovirus-delivered TFE3 but also endogenous TFE3 proteins
were localized in the nucleus of Flcn-null (Flcn
2/2) MEFs, whereas
TFE3 was localized in the cytoplasm of the Flcn heterozygote
(Flcn
f/2) MEFs (Fig. 4A and S2A). Immunohistochemical staining
exhibited nuclear or nuclear/cytoplasmic TFE3 staining in the
tumor cells from BHD patients (Fig. 4B and S2B) although the
intensity was not as strong as in the t(X;1)(p11.2;q21) translocation
alveolar soft part sarcoma involving TFE3 (Fig. S2B). Diffused
cytoplasmic TFE3 staining was observed predominantly in the
embedded normal renal tubules and in the normal kidney adjacent
to tumor although some cytoplasmic/nuclear staining was also
observed (Fig. 4B, top left). In accordance with the TFE3 staining
pattern, GPNMB expression was restricted to renal tumor cells
and was absent from embedded normal renal tubules (Fig. 4B,
bottom left). Nuclear TFE3 staining was observed in the cystic
mouse kidneys resulting from Ksp-Cre-mediated Flcn inactivation
(Fig. 4B, bottom right). UOK257 xenograft tumors showed strong
nuclear TFE3 staining whereas the adjacent mouse kidneys
showed weak and diffused cytoplasmic or cytoplasmic/nuclear
TFE3 staining (Fig. 4B, top right).
GPNMB expression was high in renal tumors from BHD
patients and a Flcn
+/2 heterozygous knockout mouse
model
We examined GPNMB expression as a readout of TFE3
transcriptional activity in the renal tumors from BHD patients. All
of the tumors (N=14) from BHD patients expressed 40-fold
higher levels of GPNMB mRNA on average (P,0.001) compared
to normal kidney tissues (N=8) (Fig. 5A). Western blots also
showed high levels of GPNMB protein expression in all of the
tumors from BHD patients (N=11) but undetectable levels of
GPNMB expression in all normal kidney tissues (N=5) (Fig. 5B).
Immunohistochemical staining further confirmed that GPNMB
expression was exclusively located in the tumor portion but not in
the normal kidney portion of sections from BHD patients and
Flcn
+/2 heterozygote mouse renal tumors (Fig. 5C). The UOK257
xenograft tumors were also strongly positive for GPNMB staining
(Fig. 5C). These results showed that TFE3 transcriptional activity
was elevated in renal tumors with FLCN inactivation.
Identification of the downstream target genes regulated
by TFE3 and FLCN
We wanted to find the downstream target genes of TFE3 other
than GPNMB, which are also dysregulated by the inactivation of
FLCN. In order to find these genes, we performed microarray
analysis of UOK257-2 cells after siRNA knockdown of TFE3 and
FLCN independently or together. We identified ,110 genes that
were regulated positively more than 1.5 fold by FLCN knockdown
and negatively by TFE3 knockdown (Table S2). In order to
identify the genes that were directly regulated by TFE3, we
examined the gene promoters for MiTF/TFE recognition
sequences using the MatInspector program (www.genomatix.de).
We found 48 genes that have one or more MiTF/TFE binding
site(s) in their promoters (Table S3). We compared those genes
identified by microarray with the reported MiTF and TFEB
targets [36,35]. Eighteen of them were among the reported targets
of either MiTF or TFEB (Fig. 6A). Interestingly, 6 lysosomal genes
and the FLCN interacting protein FNIP2 were regulated by
TFE3. The expression changes of two representative lysosomal
genes (ACP5 and ASAH1), FNIP2 and SULT1C2 were confirmed
by RT-PCR following TFE3, FLCN or TFE3/FLCN knockdown
in UOK257-2 cells (Fig. S3).
Increased TFE3 dependent cell detachment by FLCN
knockdown
UOK146 cells expressed a high level of PRCC-TFE3 fusion
protein and grew on culture dishes with typical morphological
characteristics. We observed a few detaching cells and circular
areas devoid of cells during cell culture (Fig. 6B, top left), which
were dependent on TFE3 expression since these phenotypes were
completely abrogated by TFE3 knockdown (Fig. 6B, bottom left).
Cell detachment was greatly increased by FLCN knockdown with
two independent siRNAs leaving isolated clumps of cells loosely
attached to the dish (Fig. 6B, upper panels, middle and right). Cell
detachment began about 48 hrs after siRNA transfection and
became more severe as time progressed. Conversely, cell
detachment by FLCN knockdown was dramatically attenuated
by TFE3 knockdown (Fig. 6B, lower panels, middle and right).
Discussion
In this study, in an effort to elucidate FLCN function we sought
to find downstream target genes that were regulated by FLCN and
the transcription factors that mediated such regulation. We
initially found that GPNMB expression was strictly dependent
on FLCN inactivation in most of the cell types we examined. Then
we tested whether GPNMB expression could be regulated by
TFE3 since the GPNMB promoter contained a highly conserved M
box sequence that could be recognized by MiTF/TFE transcrip-
tion factors. Our results showed that GPNMB expression was
regulated by TFE3 and that TFE3 activity was induced through its
nuclear localization as a result of FLCN inactivation. TFE3 nuclear
localization was correlated with reduced phosphorylation of
TFE3. Here we provide evidence for a new signaling pathway
that leads to the activation of an oncogenic transcription factor
TFE3 by a mechanism that is different from Xp11.2 transloca-
TFE3 Activity Induced by FLCN Inactivation
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suppressor FLCN to activation of an oncogenic transcription factor
TFE3, both of which are important in the development of RCC.
This study demonstrates the usefulness of GPNMB as a
surrogate marker for TFE3 activity and FLCN inactivation.
GPNMB expression was highly dependent on FLCN inactivation
not only in cultured cells but also in the kidneys and renal tumors
of the human patient and in vivo mouse models. Specifically, high
levels of GPNMB expression were found in all of the renal tumors
(N=11) from BHD patients, but none of the normal kidney tissues
(N=5), suggesting that GPNMB might serve as a biomarker for
BHD syndrome and a therapeutic target for treatment of BHD
renal tumors (Fig. 5). GPNMB is highly expressed in several tumor
types such as melanoma, glioblastoma and breast cancer [15–17].
Since MiTF is often amplified in melanoma, GPNMB expression
in melanoma cells is likely to be a result of elevated MiTF
transcriptional activity. However, the transcription factor that is
responsible for the GPNMB expression in glioblastoma and breast
cancer has not been investigated. Thus, it would be interesting to
investigate whether FLCN and TFE3 are involved in the
regulation of GPNMB in those tumors. We are also considering
the possibility that an antibody-drug conjugate targeting GPNMB
might be useful as a therapeutic intervention in BHD patients.
In addition to GPNMB, we have found through microarray and
promoter sequence analysis at least 47 more potential downstream
targets of TFE3 that have MiTF/TFE binding sites in their
promoter regions (Table S3). These genes may be important in
TFE3-mediated tumorigenesis and tumor cell survival and
proliferation. From among the 48 genes, we have identified 18
genes that were known targets of MiTF and/or TFEB, suggesting
that they are commonly regulated by MiTF/TFE transcription
factors (Fig. 6A). Interestingly, FNIP2 was shown to be regulated
by both TFEB and TFE3, and its promoter harbors a highly
conserved M box sequence (Fig. S4). Since expression of FLCN/
FNIP2 suppresses TFE3 activity, TFE3 mediated FNIP2 induction
could be a negative feedback mechanism. Further study of FNIP2
function and expression is needed to reveal the details of such a
mechanism.
Figure 4. Nuclear localization of TFE3 in FLCN inactivated cells. (A) Cells were plated on chamber slides and transduced with adenovirus
expressing TFE3 alone or with FLCN. TFE3 proteins were probed with rabbit polyclonal TFE3 antibody (1:450 dilutions) as described in Materials and
Methods. Nuclei were counter-stained with DAPI. (B) Immunohistochemical staining of TFE3 or GPNMB in the renal tumors from BHD patients, and
immunostaining of TFE3 in the UOK257 xenograft tumors from nude mice and in the cystic kidneys of Flcn
f/2/KspCre mice. Arrows, the normal renal
tubules imbedded in tumor cells. Asterisks (*), the renal epithelial cells detaching from tubules.
doi:10.1371/journal.pone.0015793.g004
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regulation of lysosome biogenesis and function through its binding
to CLEAR elements (GTCACGTGAC) in the promoters of many
lysosomal genes [35]. The CLEAR consensus sequence overlaps
the E-box sequence (CACGTG) and is similar to the MiTF/TFE
consensus sequence (TCACATGA). Several lysosomal genes
(ACP5, ASAH1, NEU1, HEXA, C1orf85 and CTSD) that were
shown to be regulated by TFEB were also regulated by TFE3 and
FLCN (Fig. 6A). Thus it would be interesting to examine whether
FLCN inactivation and concomitant TFE3 activation affect
lysosomal biogenesis and function through the transcriptional
regulation of those lysosomal genes.
Translocation-induced overexpression of TFE3 or TFEB fusion
proteins is important in proliferation, anchorage independent
growth, migration and long term survival of cancer cells [37,11].
Since the fusion proteins strongly stained in the nucleus and retain
DNA binding domains, it is likely that nuclear accumulation and
transcriptional activities of TFE3 and TFEB are indispensable for
their tumorigenic activity. In support of this idea, ectopic
expression of wild-type, unfused TFE3 stimulates anchorage
independent tumor cell growth [6]. In addition, Alpha-TFEB
gene fusions were found in primary renal tumors, which could
result in the expression of intact TFEB proteins through strong
Alpha gene promoter activity. This would suggest that dysregulated
expression, rather than altered function of TFE3 and TFEB fusion
proteins, may confer the tumorigenic potential of TFE3 and TFEB
[6]. Although TFE3 protein expression was not elevated, TFE3
transcriptional activity, as revealed by GPNMB expression, was
greatly induced by FLCN inactivation. Thus it is likely that
elevated TFE3 transcriptional activity as a consequence of FLCN
inactivation contributes to the development of renal carcinoma.
Nucleocytoplasmic shuttling is one of the major mechanisms in
the regulation of transcription factors including MiTF and TFEB
[38,35]. However, the regulation of TFE3 nucleocytoplasmic
shuttling has not been described. This study is the first report
showing the regulation of TFE3 nucleocytoplasmic shuttling. We
have shown that nuclear localization of TFE3 was correlated with
TFE3 post-translational modifications including decreased phos-
phorylation and an undetermined modification that induces
accumulation of TFE3
89 kDa over TFE3
72 kDa. Transcription
factors can be either imported into the nucleus or exported to
the cytoplasm depending on the stimulus. Nucleocytoplasmic
shuttling of transcription factors are often accompanied by post-
translational modifications including phosphorylation/dephos-
phorylation, sumoylation, and ubiquitination. Although TFE3
phosphorylation and sumoylation are reported, their relevance to
nucleocytoplasmic shuttling has not yet been investigated [39,40].
Thus an in-depth investigation of the relationship between the
post-translational modifications and the nucleocytoplasmic shut-
tling of TFE3 would potentially reveal the mechanism by which
FLCN inactivation regulates TFE3 activity.
Our current research effort is directed toward finding an answer
to the question of how FLCN regulates TFE3 post-translational
modifications. In order to answer that question, future experiments
will examine kinases/phosphatases that regulate TFE3 phosphor-
ylation/dephosphorylationand theundetermined post-translational
modification that increases accumulation of TFE3
89 kDa.I n
addition, it will be important to investigate the possible involvement
of FLCN, FNIP1/2 and AMPK in the regulation of TFE3. Our
current data suggested that FLCN and FNIP1/2 suppress TFE3
transcriptional activity synergistically. We showed that ectopic
FLCN expression did not suppress GPNMB promoter activity in
Figure 5. High level of GPNMB expression in the renal tumors from BHD patients and Flcn heterozygous knockout mice. (A) GPNMB
mRNA and (B) protein expressions were measured by quantitative RT-PCR and Western blotting, respectively in the renal tumors and normal kidneys.
(C) Immunohistochemical staining of GPNMB in the tumors adjacent to normal kidneys from BHD patients or Flcn-heterozygous knockout mice.
GPNMB staining in the UOK257 xenograft tumors grown in nude mice.
doi:10.1371/journal.pone.0015793.g005
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sion of FNIP1 suppressed GPNMB promoter activity in HT1080. In
addition both FLCN/FNIP1 and FLCN/FNIP2 suppressed basal
and TFE3-induced GPNMB promoter activity in HT1080 cells. An
important question remains as to whether AMPK is involved in the
regulation of TFE3. It has been reported that TFE3 induces the
expression of metabolic genes such as IRS2, HK2 and INSIG1,
resulting in glucose uptake, glycogen synthesis and protein synthesis
in the liver [41]. Since AMPK is a kinase that is activated in cells
with low energy and regulates cellular proteins that are involved in
energy metabolism, it could be possible that AMPK regulates TFE3
directly or indirectly through FLCN/FNIP or under the regulation
of FLCN/FNIP. TFE3 post-translational modifications and its
subcellular localization could be an important readout for the
analysis of FLCN function and the function of the FLCN/FNIP1/
FNIP2/AMPK complex. Further study will clarify the functional
relationship between FLCN, FNIP1, FNIP2 and AMPK.
In conclusion, we have identified a specific member of the
MiTF/TFE family of transcription factors, the oncogenic
transcription factor TFE3, that was regulated by the inactivation
of the FLCN tumor suppressor gene through induction of TFE3
nuclear localization. TFE3 nuclear localization was correlated
with decreased phosphorylation and increased accumulation of
TFE3
89 kDa over TFE3
72 kDa. We characterized GPNMB as a
downstream target of TFE3, whose expression was strictly
dependent on FLCN inactivation in cultured cells, kidneys of Flcn
knockout mouse models, and kidney tumors from BHD patients (a
working model is shown in Fig. S5). This study will shed light on
the understanding of FLCN/FNIP1/FNIP2/AMPK function and
the downstream target genes and signaling pathways that are
important in tumorigenesis, providing insight into therapeutic
targets for treatment of renal tumors that develop in BHD
syndrome and translocation RCC.
Materials and Methods
Cell culture, reagents and transfections
UOK257 cells harboring mutation in FLCN (c.1285dupC) and
their subclones expressing either wildtype (UOK257-2 and
UOK257-4) or mutant FLCN (UOK257-H255R) are described
Figure 6. The genes and the biological processes positively regulated by TFE3 and negatively regulated by FLCN. (A) Identification of
TFE3 downstream target genes that were positively regulated by FLCN knockdown. UOK257-2 cells were transfected with siRNAs targeting FLCN,
TFE3 or FLCN/TFE3. Gene expressions were examined with Human Genome U133 Plus 2.0 Array. A subset of genes that were commonly regulated by
MiTF/TFE transcription factors and by FLCN are shown in the graph. *, lysosomal genes. (B) UOK146 cell detachment was enhanced by FLCN
knockdown but suppressed by TFE3 knockdown. UOK146 cells were transfected with siRNAs targeting FLCN and/or TFE3, and cell morphology was
photographed 30 hrs after transfection. Boundaries of detached areas that are difficult to see are denoted by dotted red lines. Detached areas were
quantitated using ImageJ software (NIH, USA) and denoted as a percentage on the lower right corner of each figure.
doi:10.1371/journal.pone.0015793.g006
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f/2) were
generated from E13.5 mouse embryos harboring floxed and
deleted Flcn alleles [32]. Flcn-null MEFs (Flcn
2/2) were produced
from Flcn
f/2 MEFs by adenovirus expressing Cre recombinase.
Flcn
f/2 (B1, C1, D1 and D2) and Flcn
2/2 (CA21, CA31 and
DA21) MEF clones were obtained through spontaneous immor-
talization. UOK146 cells containing the translocation that results
in the fusion of PRCC at 1q21.2 to the TFE3 gene at Xp11.2 are
described [5]. Cells were cultured in DMEM medium supple-
mented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin. Cells were transfected with siRNAs using Dharma-
fect 4 (Dharmacon) according to the manufacturer’s protocol. The
following siRNAs were used for transfection. Human FLCN
siRNA (siFLCN1, Thermo Scientific, J-009998-05-0005); Non-
targeting siRNA pool (sc1, Thermo Scientific, D-001810-10-20);
Stealth siRNAs targeting FLCN (Invitrogen): siFLCN2 (59- CAC-
CCGGGAUAUAUCAGCCAUGAUA-39), siFLCN3 (59- CAAG-
GUGUUUGAGGCAGAGCAGUUU-39); Stealth non-targeting
scrambled siRNAs (Invitrogen): sc2 (59-CACGGGAUAUAUGA-
CACCGUCCAUA-39), sc3 (59- CAAUUGUGAGUGACGAC-
GAGGGUUU-39); Human TFE3 siRNA pool (siTFE3, Thermo
Scientific, L-009363-00-0005); Mouse Flcn siRNA pool (siFlcn,
Thermo Scientific, L-050651-01-0005). HT-1080 cells were
infected with the retroviruses expressing FLCN shRNA [31],
and selected against puromycin (2.5 mg/ml). Adenoviruses ex-
pressing wildtype or mutant (c.1285dupC) FLCN have been
described [31]. Adenoviruses expressing wildtype or dominant
negative TFE3 have been described [41].
Immunoblotting
Cells were washed with cold PBS and lysed in RIPA or Laemmli
Sample buffer supplemented with b-mercaptoethanol, benzonase
and MgCl2 (2 mM) (Biorad). Cell lysates were resolved by 4–20%
or 7.5% SDS PAGE (Bio-Rad) and blotted onto nitrocellulose
membrane using iBlot Dry Blotting System (Invitrogen). The
following antibodies were used in this study: anti-FLCN [22], anti-
FNIP1 [22], anti-b-actin (Sigma), anti-TFE3 (Santa Cruz, sc-
5958), anti-GPNMB (R&D systems, AF2550), anti-GPNMB
(Celldex Therapeutics, CR011) and anti-CREB (Cell Signaling,
9197) antibodies. Immunoblots were processed by the SuperSignal
West Pico Chemiluminescent Detection System (Thermo Scien-
tific) according to the manufacturer’s protocols.
RNA isolation, Quantitative real-time reverse
transcription-PCR (RT-PCR), and microarray
Total RNAs were isolated from cells, tumors and kidney tissues
using Trizol reagent (Invitrogen) and further purified using
RNeasy mini kit (QIAGEN) according to the manufacturer’s
protocols. To confirm GPNMB expression, quantitative real-time
reverse transcription PCR (RT-PCR) was performed as described
[31]. Quantitative RT-PCR was performed with Power SYBR-
Green or Taqman Gene Expression Master Mix (Applied
Biosystems) using a 7300 Real-Time PCR system (Applied
Biosystems) following the manufacturer’s protocols. All reactions
were run in triplicate using b-actin, GAPDH or cyclophilin A genes as
internal controls. The gene-specific primer pairs for the PCR
reactions are as follows: human FLCN forward 59- TTCACGC-
CATTCCTACACCAGA -39 and reverse 59- GCCCACAGGTT-
GTCATCACTTG -39, mouse Flcn forward 59- ACCATGGAA-
GACAGCAAGCAT-39 and reverse 59- TGCACGTGACCTGA-
GAAGTCA-39, human GPNMB forward 59- TGCGAGAT-
CACCCAGAACACA-39 and reverse 59-CGTCCCAGACCCA-
TTGAAGGT-39, mouse Gpnmb forward 59-CCAGCCACTTCC-
TCAACGA-39 and reverse 59-CCAGTGTTGTCCCCAAAGT-
TC-39, ACP5 forward 59-CGCTCCCTTCGCAAAGTG-39;
reverse 59-TGCCAAGGTGGTCATGGTTT-39; ASAH1 forward
59-GCGGCCTCTGAGACATGAAG-39, reverse 59-AGGTCA-
GACAGCTGCAGTGTTC-39; FNIP2 forward 59-CTCACTTC
TGGCGGGCTACT-39, reverse 59-GGTCCCATGAAGCA-
CAAGATC-39; SULT1C2 forward 59-CTGAGCGCCCCCG-
TAAC-39, reverse 59-GAAGCAGACGGCAATTGCA-39. PCR
product quality was monitored using post-PCR dissociation curve
analysis. For expression microarray, probes were generated by 39
in vitro transcription kit (Affymetrix) using total RNAs following
their instruction. Human Genome U133 Plus 2.0 arrays
(Affymetrix) were used for probe hybridization and processed
according to recommended protocols. The CEL files were
processed using the Partek Genomic Suite 6.4 (Partek Inc.). Data
were transformed using a log normalization process and the
differentially expressed genes were filtered using Microsoft Excel
software.
Immunohistochemistry
Renal tumors were resected from BHD patients and kidneys
were collected from Flcn-heterozygous or kidney-specific condi-
tional Flcn knockout mice [24,26]. Five micron-thick, paraffin
embedded tissue sections were treated with either proteinase K
solution (DAKO RTU) at RT for 10 min for GPNMB or
microwave heating in TE buffer (pH 8.0) for 20 min for TFE3
staining. After blocking, slides were incubated with biotinylated
goat-anti-human GPNMB (R&D Systems, AF2550), biotinylated
anti-GPNMB (Celldex Therapeutics, CR011) or with anti-TFE3
antibody (Sigma, HPA023881) for 30 min at room temperature at
1:100 and 1:500 dilutions respectively.
Immunocytochemistry
Cells were cultured on chamber slides (LAB-TEK) and
transduced with adenovirus expressing TFE3 (506 MOI). 24 hr
after transduction, cells were fixed with 4% paraformaldehyde
solution for 5 min and permeabilized with 0.3% Triton X-100.
After washing three times with PBS and blocking with 5% BSA
for 1 hr, cells were labeled with rabbit polyclonal anti-TFE3
antibody and then incubated with AlexaFluor 546 conjugated
anti-rabbit antibody. Cells were covered with coverslips with
Prolong Gold Antifade reagent (Invitrogen). Subcellular localiza-
tion of TFE3 was examined under fluorescence microscope (Carl
Zeiss).
Cytoplasmic, and soluble and insoluble nuclear extracts
preparation
Nuclear and cytoplasmic fractionation was performed basically
following the protocol described by Andrews and Faller with
minor modifications [43]. Cells were washed and resuspended in
buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2,1 0m M
KCl, 0.5 mM DTT and 0.1% NP-40) containing Complete
proteinase and PhosphoSTOP phosphatase inhibitor cocktails
from Roche. After 10 min of swelling, cells were vortexed for
10 sec and centrifuged for 10 sec. The supernatant was used as the
cytoplasmic fraction. The pellets were resuspended in buffer C
(20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA and 0.5 mM DTT, 0.1% NP-40)
containing proteinase and phosphatase inhibitor cocktails, incu-
bated on ice for 20 min and centrifuged for 2 min. The
supernatant was used as soluble nuclear extracts. The resulting
pellets were resuspended in Laemmli Sample Buffer (Bio-Rad)
containing benzonase and 2 mM MgCl2 and designated as
insoluble nuclear extracts.
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Nuclear extracts were isolated from UOK257 cells infected with
adenovirus expressing TFE3 as described above. Probe DNAs
were labeled with biotin using Biotin 39 End DNA Labeling Kit
from Thermo Scientific. Nuclear extracts were incubated with
biotin-labeled probes for 30 min at room temperature and
separated by electrophoresis through 6% DNA retardation gels
from Invitrogen. Probe DNAs were detected using LightShift
Chemiluminescent EMSA Kit (Thermo Scientific) following
manufacturer’s instructions. Probe and competitor DNAs used in
EMSA included wildtype M box (59-CCGCTTAATACCATCA-
CATGATCCTCC-39) and mutant M box (59-CCGCTTAA-
TACCATCTCGAGATCCTCC-39). A nuclear factor 1 probe
was used as a control (59-TTTTGGATTGAAGCCAATAT-
GATA-39). TFE3/probe complex formation was competed with
200 fold excess amounts of unlabeled oligonucleotides containing
wildtype M box or mutant M box. TFE3/probe band was super-
shifted with anti-TFE3 antibody.
Luciferase assay
GPNMB promoter reporter plasmid was described and kindly
provided by N.A. Meadows [12]. Reporter plasmid DNAs were
transfected into HT1080 cells along with TK promoter-driven
renilla luciferase reporter plasmid (Promega, pGL4.74) using
Lipofectamine 2000 reagent (Invitrogen). Cells were harvested
24 hrs after transfection and luciferase activity was measured using
Dual-luciferase Reporter Assay system (Promega) following the
manufacturer’s instruction.
Patient tumor samples, and care and use of animals
Approval was obtained from the NIH Institutional Review
Board for this study. Written informed consent was obtained from
patients for collection of human tumor tissue. All animal studies
were conducted in an AAALAC-accredited facility, in compliance
with the US Public Health Service guidelines for the care and use
of animals in research under protocols (ASP#07-063) approved by
the ACUC at the NCI-Frederick.
Supporting Information
Figure S1 FLCN expression is inversely correlated with
GPNMB mRNA expression. (A) Quantitative RT-PCR of
GPNMB expression in the UOK257 cells expressing either
wildtype or mutant FLCN. P, parental; HR, H255R. (B) FLCN
knockdown induced GPNMB protein expression. (C) Adenovirus-
mediated wild-type FLCN but not mutant FLCN (c.1285dupC)
expression suppressed GPNMB protein expression. (D) Gpnmb
mRNA expressions in Flcn heterozygous (B1, C1, D1 and D2) and
Flcn-null (CA21, CA31 and DA21) MEFs. f, floxed allele; -, deleted
allele. (E) Gpnmb mRNA expressions in the kidneys with Flcn
inactivation by kidney specific Cre recombinase (Ksp-Cre)
transgene expression.
(PDF)
Figure S2 Nuclear localization of TFE3 in the Flcn-null
MEFs. (A) Cells were plated on chamber slides and TFE3
proteins were probed with rabbit polyclonal anti-TFE3 antibody
(1:450 dilutions) as described in Materials and Methods. Nuclei
were counter-stained with DAPI. (B) Immunohistochemical
staining of TFE3 in the renal tumors and adjacent normal kidney
tissues from BHD patients, and in the alveolar soft part sarcoma.
(PDF)
Figure S3 Regulation of ASAH1, ACP5, FNIP2 and
SULT1C mRNA expression by FLCN and TFE3. Quanti-
tative RT-PCR of ASAH1, ACP5, FNIP2 and SULT1C2
expression after FLCN and/or TFE3 knockdown by siRNA in
UOK257-2 cells.
(PDF)
Figure S4 A highly conserved M-box sequence in the
FNIP2 ortholog promoters. FNIP2 ortholog promoter se-
quences were obtained from the Ensembl database (www.ensembl.
org) and aligned with Clustalx (1.8) software.
(PDF)
Figure S5 A model of regulation for TFE3 transcrip-
tional activity by FLCN inactivation. FLCN inactivation
induces dephosphorylation and an additional post-translational
modification of TFE3 that are necessary for its nuclear import and
retention, and transcriptional activity. P, phosphorylation; PTM,
post-translational modification; Enz, Enzyme; PPase, protein
phosphatase.
(PDF)
Table S1 The genes up- or down-regulated by FLCN
expression in UOK257 cells.
(PDF)
Table S2 The list of genes induced by FLCN siRNAs and
reduced by TFE3 siRNAs.
(XLS)
Table S3 The list of TFE3 regulated genes with MiTF/
TFE binding sequence in their promoters.
(XLS)
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